Quotient Sciences, a CDMO that specializes in “niche and smaller volume” drugs, has extended a deal with Ipsen to manufacture Sohonos (palovarotene) capsules. Sohonos is currently the only medication approved by the FDA to treat the ultra-rare disease fibrodysplasia ossificans progressiva.
CDMO Quotient extends Ipsen supply pact for rare disease drug Sohonos
Latest from Blog
Why Walmart Moved ALOHA From the Nutrition Aisle to Grocery
Nosh spoke with company leaders about what prompted the move, how they’ll measure success and why they believe protein bars are increasingly becoming just another grocery staple. Post Views: 3
Fish Oil Supplements May Be A Bust For Alzheimer’s Prevention MedNews
FRIDAY, June 19, 2026 Millions of Americans take fish oil supplements hoping to keep their brains sharp as they age.But evidence just published in the journal E Post Views: 0
RFK Jr. Talks Nutrition In Holland
(Holland, MI) – U.S. Health and Human Services Secretary Robert F. Kennedy Jr. discussed nutrition and food ac… Post Views: 3
5 Risky Wellness Trends Doctors Want You to Avoid
Bee venom therapy and raw milk are among some of the worst wellness trends this year. Post Views: 3
Prehab Can Boost Seniors’ Recuperation From Spinal Fusion Surgery, Trial Finds MedNews
FRIDAY, June 19, 2026 Prehabilitation can help the elderly recover better and suffer fewer complications from spinal fusion surgery, a new study says.Patients 7 Post Views: 0